UBS adjusted its price target for The RealReal to $14 from $16 while maintaining a neutral rating. The firm anticipates the company's upcoming Q3 results to have limited impact on Wall Street's outlook, despite projecting slightly higher adjusted EBITDA than consensus.
UBS analysts adjusted their price target for The RealReal (REAL) from $16 to $14, while keeping a 'neutral' rating. This adjustment reflects a slight recalibration of valuation expectations, but the core sentiment remains unchanged. The firm's projection of 14% year-over-year revenue growth and adjusted EBITDA exceeding consensus by a small margin suggests continued operational performance, but UBS believes this is largely priced in. For traders, this indicates that the upcoming Q3 earnings, while potentially showing modest outperformance on EBITDA, are unlikely to be a significant catalyst for the stock, reinforcing the 'neutral' stance in the short term. The long-term outlook remains tied to the company's ability to sustain double-digit growth and improve profitability beyond current market expectations.